Abstract
Ischemic mitral regurgitation occurs relatively frequently in patients with coronary
artery disease and is associated with an increased long-term risk. The pathophysiology
of ischemic mitral regurgitation is vexing and poses both diagnostic and therapeutic
challenges, leading to the need for a comprehensive, multidisciplinary approach. The
management is largely focused on medical therapy, and for those eligible, coronary
revascularization or cardiac resynchronization therapy may be considered. In select
patients, mitral valve surgery or catheter-based therapy may be undertaken with careful
consideration of the underlying pathophysiology, surgical risk, and expected long-term
outcomes. The appropriate evaluation of patients with ischemic mitral regurgitation
involves a careful multidisciplinary approach that carefully considers symptomatology,
the etiology and severity of the mitral regurgitation, and the assessment of comorbidities
and operative risk to individualize the care of these patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Burden of valvular heart diseases: a population-based study.Lancet. 2006; 368: 1005-1011
- 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2014; 63: e57-e185
- Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts.Circulation. 2005; 112: 745-758
- Contribution of ischemic mitral regurgitation to congestive heart failure after myocardial infarction.J Am Coll Cardiol. 2005; 45: 260-267
- Mitral regurgitation.Lancet. 2009; 373: 1382-1394
- Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment.Eur Heart J. 2010; 31: 2996-3005
- The prognostic role of mitral regurgitation after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.Catheter Cardiovasc Interv. 2012; 80: 779-786
- Design of a new surgical approach for ventricular remodeling to relieve ischemic mitral regurgitation: insights from 3-dimensional echocardiography.Circulation. 2000; 101 (Fig 9 – Mechanisms): 2756-2763
- Mitral regurgitation after myocardial infarction: a review.Am J Med. 2006; 119: 103-112
- Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation.Circulation. 2005; 111: 295-301
- Long-term outcomes of patients with mitral regurgitation undergoing percutaneous coronary intervention.Am J Cardiol. 2007; 100: 1218-1223
- Mechanistic insights into ischemic mitral regurgitation: echocardiographic and surgical implications.J Am Soc Echocardiogr. 2011; 24: 707-719
- Ischemic mitral regurgitation: long-term outcome and prognostic implication with quantitative Doppler assessment.Circulation. 2001; 103: 1759-1764
- 2017 ACC expert consensus decision pathway on the management of mitral regurgitation.J Am Coll Cardiol. 2017; 70: 2421-2449
- Practice variation among cardiovascular physicians in management of patients with mitral regurgitation.Am J Cardiol. 2009; 103: 255-261
- Mitral regurgitation in early myocardial infarction. Incidence, clinical detection, and prognostic implications. TIMI Study Group.Ann Intern Med. 1992; 117: 10-17
- Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.J Am Soc Echocardiogr. 2003; 16: 777-802
- Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance.J Am Soc Echocardiogr. 2017; 30: 303-371
- Defining “severe” secondary mitral regurgitation: emphasizing an integrated approach.J Am Coll Cardiol. 2014; 64: 2792-2801
- 2016 update to The American Association for Thoracic Surgery (AATS) consensus guidelines: Ischemic mitral valve regurgitation.J Thorac Cardiovasc Surg. 2017; 153: e97-e114
- Accuracy of intraoperative transesophageal echocardiography for estimating the severity of functional mitral regurgitation.Am J Cardiol. 1995; 76: 508-512
- Quantitative assessment of mitral regurgitation: how best to do it.JACC Cardiovasc Imaging. 2012; 5: 1161-1175
- Quantitation of mitral regurgitation.Circulation. 2012; 126: 2005-2017
- Mitral apparatus assessment by delayed enhancement CMR: relative impact of infarct distribution on mitral regurgitation.JACC Cardiovasc Imaging. 2013; 6: 220-234
- Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications.J Am Coll Cardiol. 2009; 55: 1-16
- Dynamic mitral regurgitation—more than meets the eye.N Engl J Med. 2004; 351: 1681-1684
- SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamic for the diagnosis and management of cardiovascular disease.Catheter Cardiovasc Interv. 2017; 89: E233-E247
- 2017 AHA/ACC Focused Update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.J Am Coll Cardiol. 2017; 70: 252-289https://doi.org/10.1016/j.jacc.2017.03.011
- Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations.J Am Coll Cardiol. 2015; 65: 1231-1248
- Effect of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure.Am J Cardiol. 1999; 83: 1201-1205
- B-blockade therapy in chronic heart failure, diastolic function and mitral regurgitation improvement by carvedilol.Am Heart J. 2000; 139: 596-608
- 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2013; 127: e283-e352
- 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2013; 62: e147-e239
- Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure.Circulation. 2003; 107: 1985-1990
- Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk.Circulation. 2011; 124: 912-919
- Does coronary artery bypass grafting alone correct moderate ischemic mitral regurgitation?.Circulation. 2001; 104: I68-I75
- Treatment of moderate mitral regurgitation and coronary disease by coronary bypass alone: late results.Ann Thorac Surg. 1999; 68: 426-430
- Can late survival of patients with moderate ischemic mitral regurgitation be impacted by intervention on the valve?.Ann Thorac Surg. 2002; 74: 1468-1475
- Surgical treatment of moderate ischemic mitral regurgitation.N Engl J Med. 2014; 371: 2178-2188
- Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation.N Engl J Med. 2016; 374: 1932-1941
- Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock.Circulation. 2003; 107: 279-284
- Percutaneous versus surgical revascularization in patients with ischemic mitral regurgitation.Circulation. 2011; 124: S156-S162
- Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation.J Am Coll Cardiol. 2007; 49: 2191-2201
- Surgical management of ischemic mitral regurgitation.Circulation. 2009; 120: 1287-1293
- Ischemic mitral regurgitation: current trends and treatment.Curr Opin Cardiol. 2013; 28: 661-665
- The Cardiothoracic Surgical Trials Network: implications for clinical practice.J Thorac Cardiovasc Surg. 2017; 154: 1938-1956
- Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial.Circulation. 2012; 126: 2502-2510
- POINT: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: a randomized trial.J Thorac Cardiovasc Surg. 2009; 138: 278-285
- Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation.J Thorac Cardiovasc Surg. 2015; 149: 752-761
- Meta-analysis of short-term and long-term survival following repair versus replacement for ischemic mitral regurgitation.Eur J Cardiothorac Surg. 2011; 39: 295-303
- Mitral-valve repair versus replacement for severe ischemic mitral regurgitation.N Engl J Med. 2014; 370: 23-32
- Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation.N Engl J Med. 2016; 374: 344-353
- Percutaneous approaches to mitral regurgitation.Curr Treat Options Cardiovasc Med. 2009; 11: 476-482
- The evolution of percutaneous mitral valve repair therapy: lesson learned and implications for patient selection.J Am Coll Cardiol. 2014; 64: 2688-2700
- Percutaneous repair or surgery for mitral regurgitation.N Engl J Med. 2011; 364: 1395-1406
- Percutaneous transcatheter mitral valve replacement: an overview of devices in preclinical and early clinical evaluation.Circ Cardiovasc Interv. 2014; 7: 400-409
- Percutaneous mitral valve repair for acute mitral regurgitation after an acute myocardial infarction.J Am Coll Cardiol. 2015; 66: 91-92
- Percutaneous mitral valve-edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry.J Am Coll Cardiol. 2014; 64: 875-884
- Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study.J Am Coll Cardiol. 2014; 64: 172-181
- Initial experience with commercial transcatheter mitral valve repair in the United States.J Am Coll Cardiol. 2016; 67: 1129-1140
- Outcomes with transcatheter mitral valve repair in the United States An STS/ACC TVT registry report.J Am Coll Cardiol. 2017; 70: 2315-2327
- Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles.J Am Coll Cardiol. 2015; 66: 278-307
- Transcatheter therapies for the treatment of valvular and paravalvular regurgitation in acquired and congenital valvular heart disease.J Am Coll Cardiol. 2015; 66: 169-183
- Transcatheter mitral valve replacement for patients with symptomatic mitral valve replacement. A global feasibility trial.J Am Coll Cardiol. 2017; 69: 381-391
- Transcatheter therapy for mitral regurgitation: clinical challenges and potential solutions.Circulation. 2017; 136: 404-417
- Transcatheter mitral valve replacement: Insights from early clinical experience and future challenges.J Am Coll Cardiol. 2017; 69: 2175-2192
- Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: a consensus document from the mitral valve academic research consortium.J Am Coll Cardiol. 2015; 66: 308-321
- 2017 ESC/EACTS Guidelines for the management of valvular heart disease: The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic surgery (EACTS).Eur Heart J. 2017; 38 (Epub ahead of print): 2739-2791
- for the Intrepid Global Pilot Study Investigators. Early experience with new transcatheter mitral valve replacement.J Am Coll Cardiol. 2018; 71: 12-21
Article info
Publication history
Published online: February 28, 2018
Footnotes
Funding: None.
Conflicts of Interest: None.
Authorship: PS reports grants and personal fees from Medtronic, Boston Scientific, and Abbott, outside the submitted work.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
